Open Targets: a platform for therapeutic target identification and validation

By Gautier Koscielny, Peter An, D. Carvalho-Silva, Jennifer A. Cham, Luca Fumis, R. Gasparyan, Samiul Hasan, Nikiforos Karamanis, Michael Maguire, Eliseo Papa and 46 more. Nucleic Acids Res., 2016

460 citations recorded by the source corpus.

We have designed and developed a data integration and visualization platform that provides evidence about the association of known and potential drug targets with diseases. The platform is designed to support identification and prioritization of biological targets for follow-up. Each drug target is linked to a disease using integrated genome-wide data from a broad range of data sources. The platform provides either a target-centric workflow to identify diseases that may be associated with a specific target, or a disease-centric workflow to identify targets that may be associated with a specific disease. Users can easily transition between these target- and disease-centric workflows. The Open Targets Validation Platform is accessible at https://www.targetvalidation.org.

Subfields: Computational Theory and Mathematics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/fc7b81e9a3c1552b846e6728cb28c14f75db6e08

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

In Molecular Biology

Citations in the corpus

Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics (2019, background): “Integration of some of these data with knowledge of genetics, genomics, transcriptomics, animalmodels and literature enable the scoring and ranking of target–disease associations for target identification (28,29).”
COSMIC: the Catalogue Of Somatic Mutations In Cancer (2018, background): “A new section of the CGC, developed in collaboration with Open Targets (8), is focused on functional descriptions of cancer genes.”
The ChEMBL database in 2017 (2016, background): “However, since these other resources are different in scope, they do not all incorporate ChEMBL in full (e.g. BindingDB focuses only on binding measurements, while Open Targets incorporates data on drug–target and drug–indication linkage).”
Sequential regulatory activity prediction across chromosomes with convolutional neural networks (2017, background): “Both genes have been implicated in several immune diseases (inflammatory bowel disease, Crohn’s disease, ulcerative colitis) via variants independent of this set (Koscielny et al. 2017) , and both genes may propagate a downstream causal influence on the disease.”
Open Targets Platform: new developments and updates two years on (2018, methodology): “Our scoring framework has been described in our previous publication (3).”
The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 (2018, methodology): “We also thank the EMBL-EBI Technical Services Cluster for maintenance of the computational infrastructure, Ian Dunham (Open Targets) and Maya Ghoussaini (Wellcome Trust Sanger Institute) and Open Targets colleagues (from Biogen, Celgene, EMBL-EBI GSK, Takeda, Wellcome Trust Sanger Institute).”
Expression Atlas: gene and protein expression across multiple studies and organisms (2017, methodology): “We would also like to express gratitude to Ian Dunham, Chuang Kee Ong, Nikiforos Karamanis, Miguel Pignatelli from Open Targets for their feedback and guidance on Atlas user interface and data.”
The PRIDE database and related tools and resources in 2019: improving support for quantification data (2018, background): “From Expression Atlas, in the near future, we plan that relevant quantitative proteomics data will be disseminated into the Open Targets platform (37).”
Open Targets Platform: supporting systematic drug–target identification and prioritisation (2020, unknown): “The Open Targets Plat-form (https://www.targetvalidation.org/) provides an open source, publicly available knowledgebase and tools that enable evidence-based systematic prioritisation of targets for disease treatment (3,4).”